NCT07507513RecruitingPhase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Immunogenicity of SSGJ-627 in Subjects With Moderate to Severe Active Ulcerative Colitis (UC)
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.1 site in 1 country288 target enrollmentStarted: March 28, 2026Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 288
- Locations
- 1
- Primary Endpoint
- Number of participants with Adverse Events
Study Overview
Brief Summary
This study will evaluate the efficacy and safety of 627 in patients with UC.
Detailed Description
Ulcerative colitis (UC) is a chronic non-specific intestinal disease characterized by continuous and diffuse inflammatory changes in the colorectal mucosa. Despite the availability of advanced therapies, there remains a significant unmet medical need, such as inadequate or loss of response to one or more of the following therapies, corticosteroid dependence, or intolerance to one or more therapies. The purpose of this study is to evaluate the efficacy and safety of 627 in patients with moderate to severe UC.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 75 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Able to understand and comply with the requirements of the study protocol, and sign the written informed consent form (ICF).
- •Male or female subjects aged 18-75 years old when signing the ICF.
- •Subjects must have been diagnosed with UC for at least 3 months prior to randomization.
- •Moderate to Severe Active Ulcerative Colitis (UC).
- •Inadequate or lost response, intolerance to one or more therapies, or corticosteroid dependence.
- •Female subjects of childbearing potential and male subjects (and their female partners) must use highly effective contraception from the screening period through at least 6 months after the last dose. The subjects must have no plans for pregnancy, sperm donation, or oocyte donation during the same period (from screening through at least 6 months post-last dose).
Exclusion Criteria
- •History of severe opportunistic infection within 2 months prior to screening or randomization that remains not adequately controlled.
- •Receiving protocol-prohibited treatments prior to screening or randomization.
- •Presence of any laboratory test abnormalities during screening and/or determination by the investigator that enrollment in the study may pose uncontrollable safety risks to the subject.
- •Positive hepatitis B test result, positive hepatitis C virus antibody (HCV Ab), positive human immunodeficiency virus antibody (HIV Ab), or positive serum Treponema pallidum antibody (TP Ab) during screening, as specified in the protocol.
- •History of clinically significant cardiovascular and cerebrovascular diseases within 6 months prior to screening.
- •History of any malignancy within 5 years prior to screening or currently active malignancy.
- •Allergy to the investigational medicinal product, any of its components, or excipients.
- •History of alcohol or substance abuse within 6 months prior to screening.
- •Undergone major surgery within 6 months prior to screening or planned major surgery during the study period.
- •Blood donation or significant blood loss within 4 weeks prior to screening.
- •Participation in any drug clinical trial within 3 months prior to screening or within 5 half-lives of the investigational drug (whichever is longer).
- •Vaccination with live/attenuated live vaccines within 4 weeks prior to screening or planned vaccination during the study period.
- •Pregnant or lactating female subjects.
- •Other conditions deemed unsuitable for trial participation by the investigator.
Outcomes
Primary Outcomes
Number of participants with Adverse Events
Time Frame: During the 36-week study period
Secondary Outcomes
- Clinical remission based on Mayo Score (MMS)(Week 14)
- Clinical response based on Mayo Score (MMS)(Week 14)
- Endoscopic improvement(Week 14)
- Endoscopic remission(Week 14)
- Symptomatic remission(During the 36-week study period)
- Symptomatic response(During the 36-week study period)
- Time to achievement of symptomatic remission and symptomatic response(During the 36-week study period)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study ParticipantsNCT07286682UCB Biopharma SRL80
Not yet recruiting
Phase 2
A phase II trial to evaluate the efficacy and safety of Usnoflast for the treatment of participants with mild to moderately active Ulcerative Colitis not responding to or intolerant to oral aminosalicylates.CTRI/2025/08/092784Zydus Lifesciences Limited129
Recruiting
Phase 1
First-in-human Study of UX016 in GNEMGNE MyopathyNCT07511556Ultragenyx Pharmaceutical Inc24
Not yet recruiting
Phase 2
Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and ChemotherapyNCT07573696Wen-zhao ZHONG50
Recruiting
Phase 1
A Clinical Study of Dual-Target, Universal CAR-T Cell Therapy for Refractory Systemic Lupus ErythematosusNCT07444307Hangzhou Qihan Biotech Co., Ltd.18